Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT02517905 · ClinicalTrials.gov registry record · Phase 3

Evaluation of EXPAREL for Prolonged Postsurgical Analgesia in Subjects Undergoing Third Molar Extraction

A Phase 3 study of Dental Pain, sponsored by Pacira Pharmaceuticals.

Completed
Registry status
Phase 3
Development phase
166
Enrollment target
1
Study location

NCT02517905 is a Phase 3 study of Dental Pain that has completed, run by Pacira Pharmaceuticals. The registered enrollment target is 166 participants, below the 218-participant average among 6 other Dental Pain trials with a reported enrollment target (24% lower). The trial reports 1 study location across 1 state.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT02517905, a Phase 3 study of Dental Pain, has completed, sponsored by Pacira Pharmaceuticals.

COMPLETED
Registry status
Phase 3
Development phase
166 participants
Enrollment target
1
Study location

Study Summary

This is a Phase 3, randomized, double-blind, placebo-controlled study in subjects scheduled to undergo elective bilateral third molar extraction under local anesthesia. At least one lower mandibular third molar must involve full or partial bony impaction confirmed by visual or radiographic evidence.

Conditions Studied

Interventions

  • DRUG Placebo
  • DRUG Bupivacaine liposome

Study Locations (1)

Utah

  • Jean Brown Research - Salt Lake City

Trial Details

FieldValue
Enrollment Target 166 participants
Start Date 2015-08
Est. Completion 2016-01
Phase Phase 3

Sponsor

Pacira Pharmaceuticals

88 total trials

What the Registry Record Tells You About NCT02517905

The ClinicalTrials.gov registry entry for NCT02517905 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 166 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 218-participant average among 6 other Dental Pain trials with a reported enrollment target (24% lower). The listed sponsor is Pacira Pharmaceuticals, which has 88 total studies on file at ClinicalTrials.gov.

The record links to 1 condition, with Dental Pain appearing as the primary indexed condition, and to 2 interventions - of which Placebo is the first listed.

NCT02517905 reports 1 study location spanning 1 distinct geographic area - top geographies include Utah.

Frequently Asked Questions

What is clinical trial NCT02517905 about?

NCT02517905 is a clinical study titled "Evaluation of EXPAREL for Prolonged Postsurgical Analgesia in Subjects Undergoing Third Molar Extraction". This is a Phase 3, randomized, double-blind, placebo-controlled study in subjects scheduled to undergo elective bilateral third molar extraction under local anesthesia. At least one lower mandibular third molar must involve full or partial bony impaction confirmed by visual or radiographic evidence.

What is the current status of trial NCT02517905?

This trial is currently completed. It is a Phase 3 study. The enrollment target is 166 participants. The study started on 2015-08. Estimated completion is 2016-01.

What conditions does trial NCT02517905 study?

This clinical trial studies the following conditions: Dental Pain.

What interventions are being tested in trial NCT02517905?

The interventions under investigation include: Placebo (DRUG), Bupivacaine liposome (DRUG).

Who is sponsoring clinical trial NCT02517905?

This trial is sponsored by Pacira Pharmaceuticals, which has 88 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT02517905 being conducted?

This trial has 1 study location across Utah. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Dental Pain

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.